Atle Fund Management AB holds a focused book of 39 stocks worth $371.7M as of Q2 2026 (disclosed Jul 24, 2026, a ~45-day 13F lag). This quarter they opened Biogen Inc and trimmed Eli Lilly & Co. Their largest long position is Eli Lilly & Co at 10% of the equity book. Cloning the disclosed picks since 2024 would be +20% (+11.4%/yr). That is a simulation of the disclosed long book, not audited returns.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1381843/holdings"
Use Arkolith to show Atle Fund Management AB's latest holdings, largest changes, and filing provenance.
The reported book (valued from quarter-end) returned +24.4%, a 4.2-point gap that is the cost of the ~45-day 13F disclosure lag a real follower can't avoid.
Growth of $10,000 cloning Atle Fund Management AB's disclosed long 13F book, rebalanced on each filing date (so it reflects the ~45-day reporting lag, no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Atle Fund Management AB
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| BlackRock, Inc. | 55 / 39 | $336.4B |
| STATE STREET CORP | 55 / 39 | $182.8B |
| GEODE CAPITAL MANAGEMENT, LLC | 55 / 39 | $95.0B |
| MORGAN STANLEY | 55 / 39 | $73.2B |
| BANK OF AMERICA CORP /DE/ | 55 / 39 | $47.3B |
| UBS Group AG | 55 / 39 | $21.4B |
| WELLS FARGO & COMPANY/MN | 55 / 39 | $20.0B |
| BARCLAYS PLC | 55 / 39 | $11.2B |
Ranked by how many of Atle Fund Management AB's top 39 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Eli Lilly & Co COM | $35.8M | 29.8K | 9.6% | ▼−25% Reduced · −10K sh | |
| 2 | Merck & Co. Inc COM | $24.3M | 189.4K | 6.5% | ▲+459% Added · +156K sh | |
| 3 | Johnson & Johnson COM | $21.7M | 85.4K | 5.8% | ▼−7.5% Reduced · −7K sh | |
| 4 | Abbvie Inc COM | $16.2M | 64.3K | 4.4% | ▼−41% Reduced · −44K sh | |
| 5 | CVS Health Corp COM | $15.1M | 146.1K | 4.1% | ▲+515% Added · +122K sh | |
| 6 | Thermo Fisher Scientific Corp COM | $14.0M | 27.9K | 3.8% | ▲+21% Added · +5K sh | |
| 7 | Revolution Medicines Inc COM | $13.7M | 73.1K | 3.7% | ▼−88% Reduced · −544K sh | |
| 8 | Biogen Inc COM | $13.6M | 62.8K | 3.6% | ▲New New position | |
| 9 | Neurocrine Biosciences Inc COM | $12.3M | 72.9K | 3.3% | ▼−19% Reduced · −17K sh | |
| 10 | Mirum Pharmaceuticals Inc COM | $11.8M | 100.8K | 3.2% | ▼−49% Reduced · −95K sh | |
| 11 | Alkermes PLC SHS | $11.2M | 213.3K | 3.0% | ▼−12% Reduced · −29K sh | |
| 12 | Ionis Pharmaceuticals Inc COM | $10.9M | 137.1K | 2.9% | ▲+392% Added · +109K sh | |
| 13 | Beone Medicines Ltd-ADR SPONSORED ADS | $10.0M | 35.2K | 2.7% | ▼−16% Reduced · −7K sh | |
| 14 | Intuitive Surgical Inc COM NEW | $9.8M | 24.7K | 2.6% | ▼−65% Reduced · −46K sh | |
| 15 | Stryker Corporation COM | $9.5M | 30.3K | 2.6% | ▲+13% Added · +3K sh | |
| 16 | Vertex Pharmaceuticals Inc COM | $9.5M | 19.1K | 2.6% | ▼−17% Reduced · −4K sh | |
| 17 | Edwards Lifesciences Corp COM | $9.3M | 103.2K | 2.5% | ▼−3.1% Reduced · −3K sh | |
| 18 | Bridgebio Pharma Inc COM | $9.3M | 124.7K | 2.5% | ▲+12% Added · +13K sh | |
| 19 | Krystal Biotech, Inc COM | $8.9M | 24.0K | 2.4% | ▼−36% Reduced · −14K sh | |
| 20 | Cencora Inc COM | $8.8M | 31.1K | 2.4% | ▲+33% Added · +8K sh | |
| 21 | Newamsterdam Pharma Co NV ORDINARY SHARES | $8.4M | 248.8K | 2.3% | ▲+163% Added · +154K sh | |
| 22 | Abivax Sa SPONSORED ADS | $7.8M | 58.2K | 2.1% | ▲+84% Added · +27K sh | |
| 23 | Incyte Corp COM | $6.5M | 57.0K | 1.7% | ▲+12% Added · +6K sh | |
| 24 | Irhythm Technologies Inc COM | $6.4M | 54.1K | 1.7% | ▲+142% Added · +32K sh | |
| 25 | Boston Scientifc COM | $6.2M | 146.4K | 1.7% | ▲+262% Added · +106K sh | |
| 26 | Insmed Inc COM PAR $.01 | $6.2M | 58.4K | 1.7% | ▼−40% Reduced · −39K sh | |
| 27 | Tango Therapeutics Inc COM | $6.2M | 198.6K | 1.7% | ▲+564% Added · +169K sh | |
| 28 | Gilead Sciences Inc COM | $5.8M | 46.1K | 1.6% | ▼−3.8% Reduced · −2K sh | |
| 29 | Cardinal Health Inc COM | $5.6M | 23.6K | 1.5% | ▼−78% Reduced · −85K sh | |
| 30 | Oruka Therapeuti COM | $5.2M | 54.9K | 1.4% | ▲New New position | |
| 31 | Spyre Therapeutics Inc COM NEW | $5.1M | 57.0K | 1.4% | ▼−9.1% Reduced · −6K sh | |
| 32 | Dexcom Inc COM NEW | $4.8M | 71.8K | 1.3% | ▼−88% Reduced · −512K sh | |
| 33 | Bicara Therapeutics Inc COM | $4.3M | 145.7K | 1.2% | ▼−88% Reduced · −1.0M sh | |
| 34 | Ideaya Biosciences Inc COM | $3.5M | 94.5K | 0.9% | ▲+203% Added · +63K sh | |
| 35 | Celcuity Inc COM | $3.5M | 33.3K | 0.9% | ▼−76% Reduced · −108K sh | |
| 36 | Disc Medicine Inc COM | $3.2M | 43.7K | 0.9% | ▼−59% Reduced · −64K sh | |
| 37 | Pyxis Oncology Inc COMMON STOCK | $2.9M | 966.5K | 0.8% | ▲+390% Added · +769K sh | |
| 38 | Compass Therapeutics Inc COM | $2.3M | 1.05M | 0.6% | ▲25× Added · +1.0M sh | |
| 39 | Jade Biosciences COM NEW | $2.0M | 88.6K | 0.5% | ▲New New position |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Jul 24, 2026 | 39 | $371.7M | 13F-HR |
| Q1 2026 | Mar 31, 2026 | May 11, 2026 | 39 | $309.7M | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 6, 2026 | 39 | $313.4M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 4, 2025 | 38 | $27.0M | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Jul 14, 2025 | 37 | $233.7M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 5, 2025 | 37 | $226.5M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 4, 2025 | 36 | $210.8M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 12, 2024 | 36 | $212.8M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.